证券记录 · 已归档季度
APLS
Apellis Pharmaceuticals, Inc. · Healthcare · Biotechnology
10被追踪持有人
+2Δ持有人
20.37M持有股份
$587.46M报告持仓市值
+2新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +25.0% ·
股份流向 -3.8% ·
净新建仓位 +20.0%
— 公式
持股分散化 — 持有人增多，合计持仓比例缩小
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q1 2026 | 99 | +3 | 79.10M | $3.12B | +14 | −12 |
| Q4 2025 | 97 | +1 | 73.39M | $1.84B | +2 | — |
| Q3 2025 | 19 | +1 | 50.24M | $1.14B | +1 | −1 |
| Q2 2025 | 16 | +2 | 43.69M | $756.24M | +2 | — |
| Q1 2025 | 11 | -2 | 24.93M | $545.30M | +1 | −3 |
| Q4 2024 | 13 | +2 | 23.82M | $760.24M | +3 | −1 |
| Q3 2024 | 10 | +2 | 20.37M | $587.46M | +2 | — |
| Q2 2024 | 8 | — | 21.17M | $811.69M | — | — |
持有人 · Q3 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 7 | Geode Capital Management ✦ (被动) | 1.81M | +1.3% | $52.23M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Geode Capital Management ✦ (被动) | 1.81M | +1.3% | $52.23M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Norges Bank ✦ (被动) | 1.07M | -1.1% | $30.79M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 817.26K | +231.0% | $23.57M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 817.26K | +231.0% | $23.57M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 817.26K | +231.0% | $23.57M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 378.46K | -70.3% | $10.91M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 378.46K | -70.3% | $10.91M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 372.33K | 新增 | $10.74M | 0.0% | New | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 198.13K | +28.8% | $5.71M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 198.13K | +28.8% | $5.71M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Millennium Management ✦ | 77.39K | -62.4% | $2.23M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 58.78K | +113.4% | $1.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 20 | Marshall Wace ✦ | 21.79K | 新增 | $628,424 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Renaissance Technologies | $10.74M | 0.0% |
| Marshall Wace | $628,424 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 320 持有人, 137.95M 股份, $5.43B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2024 ·
方法论 ·
通过API获取此数据